Acadia Pharmaceuticals, Inc. (ACAD) Tops Q2 EPS by 3c
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $22.11 +2.27%
EPS Growth %: -62.5%
Financial Fact:
Net loss: -71.61M
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: -62.5%
Financial Fact:
Net loss: -71.61M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Acadia Pharmaceuticals, Inc. (Nasdaq: ACAD) reported Q2 EPS of ($0.12), $0.03 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $460 thousand versus the consensus estimate of $480 thousand.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ennis (EBF) Reports In-Line Q1 EPS
- Sonoma Pharmaceuticals (SNOA) Misses Q4 EPS by 33c
- Accenture (ACN) Tops Q3 EPS by 8c, Misses on Revenue; Offers FY26 EPS Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
